A Study Evaluating Salvage Combination Of Ipilimumab and Nivolumab in Advanced Melanoma Patients after Failure of Prior Checkpoint Inhibitor Therapy

Trial Profile

A Study Evaluating Salvage Combination Of Ipilimumab and Nivolumab in Advanced Melanoma Patients after Failure of Prior Checkpoint Inhibitor Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top